about
Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure InfectionsThe safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials.Mie scatter spectra-based device for instant, contact-free, and specific diagnosis of bacterial skin infectionUrotrauma: AUA guideline.Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycinPharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrugWorld Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infectionsSingle- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolidAntibacterial Treatment of Meticillin-Resistant Staphylococcus Aureus Complicated Skin and Soft Tissue Infections: a Cost and Budget Impact Analysis in Greek Hospitals.Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model.Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study.Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia.Characterization of Staphylococcus aureus Isolated from Non-Native Patients with Skin and Soft Tissue Infections in Shanghai.The large scale antibacterial, antifungal and anti-phage efficiency of Petamcin-A: new multicomponent preparation for skin diseases treatment.Cutaneous infections and infestations: new therapiesAcute Bacterial Skin and Skin Structure Infections Treated with Intravenous Antibiotics in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center.Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.Cryptic Bacteria of Lower Limb Deep Tissues as a Possible Cause of Inflammatory and Necrotic Changes in Ischemia, Venous Stasis and Varices, and Lymphedema.In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.Systematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection.Comparative evaluation of 2 g single dose versus conventional dose azithromycin in uncomplicated skin and skin structure infections.Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycinAntimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines ? a commentary and an alternative European approach according to clinical definitions.An FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant Staphylococcus aureus (MRSA)Impact of Antimicrobial Stewardship Program (ASP) on Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in an Acute-Tertiary Care Hospital.Real-World Treatment of Complicated Skin and Soft Tissue Infections with Daptomycin: Results from a Large European Registry (EU-CORE).UVC light prophylaxis for cutaneous wound infections in mice.Nonredundant Roles of Interleukin-17A (IL-17A) and IL-22 in Murine Host Defense against Cutaneous and Hematogenous Infection Due to Methicillin-Resistant Staphylococcus aureus.Global fluoroquinolone resistance epidemiology and implictions for clinical use.18β-Glycyrrhetinic acid inhibits methicillin-resistant Staphylococcus aureus survival and attenuates virulence gene expression.In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice.Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014.Sphingoid bases are taken up by Escherichia coli and Staphylococcus aureus and induce ultrastructural damageEfficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infectionsMoxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study.Efficacy of Lantibiotic Treatment of Staphylococcus aureus-Induced Skin Infections, Monitored by In Vivo Bioluminescent Imaging.Nanoparticle-Based Therapies for Wound Biofilm Infection: Opportunities and Challenges.Electrochemically Modulated Nitric Oxide Release From Flexible Silicone Rubber Patch: Antimicrobial Activity For Potential Wound Healing Applications.In vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection model
P2860
Q33726674-95A46799-2575-4262-AA7B-53F890981E8DQ33834856-72145F10-6694-42DB-825E-E33C5153D8DEQ33881306-4BF8CD56-1915-4865-9F57-19BC30661B6EQ33922656-629A3C90-2516-4EC1-8FB4-781FC5A2F479Q34250054-8656A765-50AE-45D8-8D42-4E45F41AAA70Q34315661-A8BD9A23-1638-4B07-9205-16FEA2BCF667Q34548251-0B249EBF-5289-46B3-907D-254D928F8FC9Q34565950-E5EDC5C2-D952-4669-9720-FCF99A4E923EQ34658779-CDA0F8B5-6C33-4B7E-BF24-B18E0E256A1DQ34726077-610DCA2A-B68C-4CA4-8ED5-51396A88C9E5Q34922452-D25D7853-2A1F-41AF-8FDA-9E5D67031416Q35155399-5F7B95C9-917B-485C-919D-BB5316D9B822Q35408518-3667E513-279A-4662-B095-21C5085A612FQ35553144-EA03BC19-67B2-4C05-9AED-F88C0F4F035BQ35624068-DF8AD9F9-C087-446E-A5EC-35D914E08CABQ35628618-F4E7CAAE-FE08-4A50-AE14-E2D924764789Q35752774-1FB49292-0ED9-4D0A-AF9E-84FF9E4DE910Q35802607-46BE1812-1701-4152-A020-FBB7A2109320Q35804232-6A383DC6-7DF2-4F58-A4F2-CBA8907926D7Q35822261-89DC1D36-8E0C-4A92-81F8-571F94E3305BQ35860102-22C33254-DDA4-4E6D-ADA4-07D44F7256D4Q35922801-769FC794-7884-4EFD-945D-F79724089813Q35959558-7D6CD35A-D852-4826-8FF7-4EE89EE47253Q35960005-EA38AF03-F64F-4723-B23A-0910A7E02132Q35973180-F044C2E3-3240-42F7-8845-316E08E9A070Q36059135-FF87D47E-2B27-4B68-AC43-97CE137A4866Q36073410-A9144A56-6EBC-4C64-87BF-6A7F7E30D5F6Q36086304-C1A8BA2E-F7B8-42E6-BCB2-F0A539088E4BQ36138054-1C8FB02F-1E22-4C7F-9555-2F1C4D2F577AQ36337074-B0CE7CF5-0EBD-4B48-B7F1-C5DB35737E82Q36505342-C6408703-FADD-49EE-A419-D3D82B1D411DQ36558524-4604BF7F-E474-4367-8DD5-9FF8567E4F4CQ36729957-B5464644-390D-4BE4-B3D6-0F8204B51417Q36790886-74445AB6-C51F-43DC-AA9C-CD255AA89C6DQ36927625-EE70BDD8-3E00-48C3-89FF-B528D890AC53Q36997690-41A6FD1F-A8A0-4AF4-953F-158BD337B7ABQ37023281-5DAFEE3C-6EE4-4AC4-830D-5E1238C5F042Q37080475-7F107753-F3E2-4B33-9ADE-5BDAEC64979BQ37255411-7B97176A-9FA8-4B72-BB1D-2351A422D934Q37263439-7054FAB6-80AF-4EEC-A3E4-AA43A2E9A227
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Complicated skin and soft tissue infection.
@en
Complicated skin and soft tissue infection.
@nl
type
label
Complicated skin and soft tissue infection.
@en
Complicated skin and soft tissue infection.
@nl
prefLabel
Complicated skin and soft tissue infection.
@en
Complicated skin and soft tissue infection.
@nl
P2860
P356
P1476
Complicated skin and soft tissue infection.
@en
P2093
Matthew S Dryden
P2860
P304
P356
10.1093/JAC/DKQ302
P407
P478
65 Suppl 3
P577
2010-11-01T00:00:00Z